Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gerpinnes – page 33

599 clinical trials in Gerpinnes, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gerpinnes at a glance
599
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

599 trials in Gerpinnes

Open in trial search

Paresis

Not recruiting

Study on the Effectiveness and Safety of NT 201 (Botulinum Toxin) for Treating Lower Limb Spasticity in Adults After Stroke or Traumatic Brain Injury

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:IncobotulinumtoxinA
  • Sponsor:Merz Pharmaceuticals GmbH

Crohn's disease

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Crohn's Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ciprofloxacin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Neoplasm malignant

Not recruiting

Study on the Safety of Avelumab, Lorlatinib, and Axitinib for Cancer Patients Continuing from Previous Trials

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Avelumab
  • Sponsor:Pfizer Inc.

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:LYSARC

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Genmab A/S

Study Comparing Radiotherapy Alone to Radiotherapy with Cisplatin for Patients with Sinus or Salivary Gland Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Unicancer

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gerpinnes

What the registry says about research in the country

01 Dermatology Research

Innovative clinical studies focusing on prurigo nodularis and hidradenitis suppurativa, evaluating novel therapeutic approaches for chronic skin conditions.

  • Itch and skin lesion management
  • Inflammatory skin disorders
  • Treatment-resistant conditions

Research aims to provide relief for patients with moderate to severe symptoms who haven't responded to conventional treatments.

02 Oncology Studies

Comprehensive research targeting various forms of gynecological cancers, including innovative treatments for ovarian, fallopian tube, and endometrial cancers.

  • Recurrent ovarian cancer therapy
  • Combined immunotherapy approaches
  • MUC16+ cancer treatments

Investigation of novel combination therapies to improve outcomes in recurrent cancers.

03 Emergency Medicine

Ground-breaking research in severe burn treatment and critical care, examining high-dose vitamin C therapy for life-threatening thermal injuries.

  • Organ dysfunction prevention
  • Burn trauma management
  • Critical care interventions

Studies focus on reducing mortality and improving outcomes in severely burned patients through innovative therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.